RxDoctor Payments Data

Damon Hoffmann, DO

Urology · Washington, PANPI 1255592663

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Intuitive Surgical at 46.3% of the total. Reporting peaked in 2021 at $16,004 and has fallen 96.6% since, to $546 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,336in general payments, 2019–2025

Across 629 payments — averaging $45.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$13K
  • Axonics, Inc.$4K
  • Medtronic$2K
  • Astellas Pharma US Inc$2K
  • Johnson & Johnson$954
  • Sumitomo Pharma America, Inc.$805
  • plus $6K from 44 others

What the payments were for

  • Travel & lodging$2,76210%
  • Food & beverage$13,21147%
  • Education$12,36344%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,336 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$243,518
Medicare patients
574
Services billed
2,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix87$230,376
MyrbetriqMirabegron150$99,193
GemtesaVibegron73$44,824
Mirabegron ErMirabegron42$22,007
Tamsulosin Hcl678$10,252
PremarinEstrogens, Conjugated11$5,044
Finasteride252$2,601
Potassium Citrate ErPotassium Citrate66$2,225
Solifenacin Succinate72$2,020
Estradiol23$1,666
Bicalutamide35$1,528
Dutasteride29$1,390
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst77$1,378
Cephalexin353$1,252
Tolterodine Tartrate ErTolterodine Tartrate22$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$805$275,200160 claims
Astellas Pharma US IncMyrbetriq$1,539$99,193150 claims
PfizerPremarin$273$5,04411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.

Other urology in Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →